Dr. Biolyse® is a device with artificial intelligence that works in sync with the immunesystem and can be integrated like an element of this system. It is designed to developchemical immunity within the body against infections. It gives electrical signals to thebody without causing any pain and suffering to the patient. The electric current itapplies is of a type that is not used in homes, and it is the frequency feature of directcurrent.The aim of this study is to evaluate the safety and efficacy of the Biolyse device. forminimizing the use of drugs in COVID-19 patients and treating drug-related organ damageduring treatment We hope that by conducting this study, we will obtain sufficient data toobtain approval (CE certification) for routine use and marketing of this medical devicein patients. Once this happens, we will be able to ensure that this device isaccessible/usable for patients suffering from similar diseases, especially COVID-19,regardless of any studies.
Not Provided
Device: Signal Therapy provided by Dr.Biolyse device
Before the application, the area where the electrodes will be cleaned with appropriate
solutions. In addition, 500-1000 ml of isotonic serum will be supplemented according to
your weight, just before the first electrical signal application during the day.
Electrical signal will be applied to the lung and upper leg area for 90 minutes in the
morning, noon, and evening on the first 3 days, 60 minutes in the morning and evening on
the 4th and 5th days, to the lung and upper leg area. During your first hospitalization,
blood will be drawn from you daily for 5 days and evaluated in terms of various
biochemical parameters and detailed molecular analyzes.
Other Name: Quantum Signal Therapy Technology
Other: Liquid Support Treatment
The control group will only receive fluid therapy and will be monitored with the same
blood parameters throughout the hospitalization.
Inclusion Criteria:
- Men and women between the ages of 18-65
- Patients with mild moderate complicated or uncomplicated COVID 19 pneumonias
- Those who accept to be followed up and treated as an inpatient
- Those who have at least one laboratory and clinical finding that can be evaluated
during follow-up
Exclusion Criteria:
- Patients with severe course or COVID 19 pneumonia requiring intensive care follow-up
- Pregnant or breastfeeding women
- Epilepsy, Arrhythmia, Dementia, heart failure, severe lung disease, patients with
active malignancy and those with pacemaker
- "Vulnerable Population" patients defined in ICU
Bezmialem Vakif University Dragos Hospital
Istanbul 745044, Turkey (Türkiye)
Serkan Chairman of the Board, Principal Investigator
AVB Biotech A.S.